AstraZeneca: COPD combo shows efficacy
(CercleFinance.com) - AstraZeneca's triple combination therapy to treat chronic obstructive pulmonary disease shows evidence of safety and efficacy, the drugmaker said over the weekend.
A Phase III trial, which evaluated PT010 (budesonide/lycopyrronium/formoterol fumarate) in moderate to very severe chronic obstructive pulmonary disease, met eight of the nine primary lung function endpoints, the company said.
In a key secondary endpoint, PT010 showed a statistically significant 52% reduction in the rate of moderate or severe COPD exacerbations compared with Bevespi Aerosphere, another combination of two COPD medicines, it added.
The data was presented yesterday at the European Respiratory Society (ERS) International Congress 2018 in Paris, France and was published in The Lancet magazine.
AstraZeneca expects to make the first regulatory submissions for PT010 in the second half of 2018.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
A Phase III trial, which evaluated PT010 (budesonide/lycopyrronium/formoterol fumarate) in moderate to very severe chronic obstructive pulmonary disease, met eight of the nine primary lung function endpoints, the company said.
In a key secondary endpoint, PT010 showed a statistically significant 52% reduction in the rate of moderate or severe COPD exacerbations compared with Bevespi Aerosphere, another combination of two COPD medicines, it added.
The data was presented yesterday at the European Respiratory Society (ERS) International Congress 2018 in Paris, France and was published in The Lancet magazine.
AstraZeneca expects to make the first regulatory submissions for PT010 in the second half of 2018.
Copyright (c) 2018 CercleFinance.com. All rights reserved.